1 | Treatment failure (i.e. virological, immunological, and/or clinical failure |
1.1 | Virological failure |
1.2 | Partial virological failure |
1.3 | Immunological failure - CD4 drop |
1.4 | Clinical progression |
1.5 | Resistance (based on test result) |
10 | Hyperlactataemie/lactic acidosis |
11 | Bone toxicity |
15 | Social contra-indication |
16 | Contra-indication unspecified |
16.8 | Contra-indication expired |
16.9 | Contra-indication – other |
17 | MTCT regimen completed |
18 | Unwanted weight changes |
2 | Abnormal fat redistribution |
3 | Concern of cardiovascular disease |
3.1 | Dyslipidaemia |
3.2 | Cardiovascular disease |
4 | Hypersensitivity reaction (skin eruption etc.) |
4.3 | Injection site reaction |
4.4 | Injection fatigue (not related to safety) |
5 | Toxicity, predominantly from abdomen/G-I tract |
5.1 | Toxicity - GI tract |
5.2 | Toxicity - Liver |
5.3 | Toxicity - Pancreas |
6 | Toxicity, predominantly from nervous system |
6.1 | Toxicity - peripheral neuropathy |
6.2 | Toxicity - neuropsychiatric |
6.3 | Toxicity - headache |
7 | Toxicity, predominantly from kidneys |
70 | Pregnancy - toxicity concerns (during pregnancy) |
75 | Pregnancy - switch to a more appropriate regimen for PMTCT |
8 | Toxicity, predominantly from endocrine system |
8.1 | Diabetes |
88 | Death |
9 | Haematological toxicity (anemia etc.) |
90 | Side effects - any of the above but unspecified |
90.1 | Comorbidity |
91 | Toxicity, not mentioned above |
91.1 | Toxicity, unspecified |
92 | Availability of more effective treatment (not specifically failure or side effect related) |
92.1 | Simplified treatment available |
92.2 | Treatment too complex |
92.3 | Drug interaction |
92.31 | Drug interaction - commencing TB/BCG treatment |
92.32 | Drug interaction - ended TB/BCG treatment |
92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) |
92.4 | Protocol change |
92.5 | Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) |
92.6 | End of empiric treatment |
92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication |
92.91 | Change to generic drug |
92.92 | Change to branded drug |
93 | Structured Treatment Interruption (STI) |
93.1 | Structured Treatment Interruption (STI) - at high CD4 |
94 | Patient's wish/decision, not specified above |
94.1 | Non-compliance |
94.2 | Defaulter |
95 | Physician's decision, not specified above |
96 | Pregnancy (see also more specific codes 70 and 75 |
96.1 | Pregnancy intended |
96.2 | Pregnancy ended |
97 | Study treatment |
97.1 | Study treatment commenced |
97.2 | Study treatment completed |
97.6 | Drug not available |
98 | Other causes, not specified above |
99 | Unknown |